

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/403,861	02/11/2000	CARLO RICCARDI	RICCARDI=1	7791
7590 03/11/2004			EXAMINER	
BROWDY AND NEIMARK			EPPS FORD, JANET L	
624 NINTH ST WASHINGTO			ART UNIT	PAPER NUMBER
,			1635	

DATE MAILED: 03/11/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

~	Application No.	Applicant(s)			
Advisory Action	09/403, 861	RICCARDI, CARLO			
Auvisory Action	Examiner	Art Unit			
	Janet L. Epps-Ford, Ph.D.	1635			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
THE REPLY FILED 11 February 2004 FAILS TO PLACE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may <u>only</u> be either: (1 condition for allowance; (2) a timely filed Notice of Appe Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applice i) a timely filed amendment whi	cation. A proper reply to a ch places the application in			
PERIOD FOR REPLY [check either a) or b)]					
a) The period for reply expires 5 months from the mailing date of					
b) The period for reply expires on: (1) the mailing date of this Adv event, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The dathave been filed is the date for purposes of determining the period of extens 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three moterned patent term adjustment. See 37 CFR 1.704(b).	an SIX MONTHS from the mailing date o FILED WITHIN TWO MONTHS OF THI te on which the petition under 37 CFR 1.1 sion and the corresponding amount of the I statutory period for reply originally set in	f the final rejection. E FINAL REJECTION. See MPEP 136(a) and the appropriate extension fee fee. The appropriate extension fee under the final Office action; or (2) as set forth in			
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.					
2. The proposed amendment(s) will not be entered because:					
(a) 🛛 they raise new issues that would require further	er consideration and/or search (see NOTE below);			
(b) ☐ they raise the issue of new matter (see Note below);					
(c) they are not deemed to place the application issues for appeal; and/or	in better form for appeal by mat	erially reducing or simplifying the			
(d) They present additional claims without canceling a corresponding number of finally rejected claims.					
NOTE: See Continuation Sheet.					
3. Applicant's reply has overcome the following rejection	ction(s):				
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a s	eparate, timely filed amendment			
5. The a) affidavit, b) exhibit, or c) request fo application in condition for allowance because:		sidered but does NOT place the			
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly			
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims w	· / /—	·—			
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed:					
Claim(s) objected to:					
Claim(s) rejected: 41-48 would remain rejected for th	e reasons of record.				
Claim(s) withdrawn from consideration:					
8. The drawing correction filed on is a) app	proved or b) disapproved by	the Examiner.			
9. Note the attached Information Disclosure Stateme	nt(s)(PTO-1449) Paper No(s).				
10.⊠ Other: <u>See Continuation Sheet</u>		Janet L. Epps-Pond Patent Examiner Art Unit 1635			

Continuation Sheet (PTOL-303) 009/403,861

Application No.

Continuation of 2. NOTE: Applicants have amended the instant claims to encompass GILR proteins capable of inhibiting apoptosis and stimulating lymphocyte activity, wherein said proteins comprise no more than ten amino acid changes from the amino acid sequence of SEQ ID NO: 2, wherein said changes are alternative conservative substitutions as defined by Table B. This amendment raises new issues under 35 USC 112, 1st paragraph since the instant claims read on an exponential number of proteins having the cited structure, however apart from trial and error experimentation de novo experimentation, there is no particular guidance to instruct the skilled artisan how to pick and chose which of these proteins would function to inhibit apoptosis and stimulate lymphocyte activity. Although Figure 15 shows an alignment between the mouse and human GILR proteins, wherein the two proteins differ at 11 positions, it is noted that the instant claims are not limited to wherein said changes occur at the 11 differential positions between the mouse and the human GILR proteins as indicated by Figure 15.

Additionally, it is noted that applicant's reference to Table B raises an objection under MPEP § 2173.05(s) which states "Where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table 'is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant's convenience."

Continuation of 10. Other: Applicant's arguments filed 2-11-04 are directed to the claims as amended. Since the amendment of 2-11-04 has not been entered, Applicant's arguments are considered moot.